?? ?Donepezil Hydrochloride (CAS 120011-70-3) - Product Overview?
Donepezil Hydrochloride is a ?highly selective acetylcholinesterase (AChE) inhibitor? (molecular formula: ?C??H??ClNO??, MW: 415.95) primarily used to ?treat mild to moderate Alzheimer’s disease (AD)?. This white crystalline powder with ≥99% HPLC purity enhances cognitive function by elevating acetylcholine levels in the brain, offering stability under ?2-8°C storage conditions? for pharmaceutical formulations.

?? ?Key Advantages?
?? ?Potent Inhibition?: Targets AChE with an IC?? of ?6.7 nM?, outperforming traditional inhibitors.
?? ?Clinical Efficacy?: Improves ADAS-cog scores by ?3-4 points? in clinical trials.
?? ?Versatile Solubility?: >50 mg/mL water solubility for easy formulation.
?? ?Safety Edge?: Minimizes peripheral cholinergic side effects.

?? ?Applications?

• ?Alzheimer’s Therapy?: Core treatment for slowing cognitive decline.

• ?Neurological Research?: Key tool for studying cholinergic pathways.

• ?Drug Development?: Used in extended-release tablets and combination therapies.

?? ?Quality Certifications?

• Complies with ?USP/EP? pharmacopeial standards.

• Batch-tested via ?HPLC (≥99%)?, ?GC?, and ?NMR?for structural validation.

• Manufactured in ?GMP?-certified facilities with ISO 9001 compliance.

?? ?Market Insights?
The global Alzheimer’s treatment market is projected to surpass ?$8 billion by 2030?, driven by aging populations. Donepezil Hydrochloride dominates ?40% of the AChE inhibitor market?, maintaining its status as a first-line therapy.